Get the Stockscreener App
139.07
0.22%
-0.30
After Hours:
138.00
-1.07
-0.77%
Illumina Inc stock is traded at $139.07, with a volume of 1.24M.
It is down -0.22% in the last 24 hours and up +9.18% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$139.37
Open:
$139.58
24h Volume:
1.24M
Relative Volume:
0.67
Market Cap:
$21.04B
Revenue:
$4.34B
Net Income/Loss:
$850.00M
P/E Ratio:
25.45
EPS:
5.4635
Net Cash Flow:
$921.00M
1W Performance:
+9.57%
1M Performance:
+9.18%
6M Performance:
+13.58%
1Y Performance:
+77.91%
1-Day Range:
$136.36
$142.41
1-Week Range:
$119.14
$142.41
52-Week Range:
$73.86
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, WAT, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
139.07 | 21.09B | 4.34B | 850.00M | 921.00M | 5.4635 |
TMO
Thermo Fisher Scientific Inc
|
466.76 | 171.91B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.63 | 123.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.97 | 44.73B | 4.30B | 1.06B | 1.04B | 13.08 |
WAT
Waters Corp
|
342.75 | 29.63B | 3.17B | 642.63M | 516.49M | 10.77 |
A
Agilent Technologies Inc
|
117.53 | 31.70B | 7.07B | 1.29B | 993.00M | 4.5355 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Uber, Exxon Mobil, Illumina, Diamondback Energy: CNBC's 'Final Trades' - MSN
Uber, Illumina And Diamondback Energy: CNBC’s ‘Final Trades’Diamondback Energy (NASDAQ:FANG), Hertz Gl - Benzinga
Epigenetics Market is expected to Hit US$ 7.10 Billion by 2033 | - openPR.com
[Latest] Global Targeted DNA RNA Sequencing Market Size/Share Worth USD 46.9 Billion by 2035 at a 18.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Illumina, Inc. Q1 2026 Financial Report: Earnings, Revenue, Risk Factors & Forward-Looking Statements 18 24 37 - Minichart
Final Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBC
Illumina Partners with Florida State University Lab for Rare Disease Genome Sequencing - Clinical Lab Products
Genomics Market size is anticipated to reach US$ 83.61 billion - openPR.com
Illumina (ILMN) Q1 2026 Earnings: Revenue Beat and Raised GuidanceNews and Statistics - IndexBox
Illumina, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ILMN) 2026-05-03 - Seeking Alpha
ILMN Q1 Deep Dive: Clinical Sequencing Fuels Growth as NovaSeq X Demand Surges - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM) - The Globe and Mail
Illumina revenue up 4.8% to USD 1.09B in Q1 2026 - Medical Buyer
Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
[10-Q] ILLUMINA, INC. Quarterly Earnings Report - Stock Titan
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina jumps 7.1% as Q1 results top expectations and full-year outlook rises - Quiver Quantitative
Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Here’s Why Illumina Stock Could Deliver 8% Annual Returns Through 2028 - TIKR.com
ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up - Yahoo Finance
Canaccord cuts Illumina stock price target on competition concerns - Investing.com UK
Illumina, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Illumina, Inc. (NASDAQ:ILMN) Q1 2026 Earnings Call Transcript - Insider Monkey
Canaccord cuts Illumina stock price target on competition concerns By Investing.com - Investing.com Canada
Illumina Q1 2026 earnings preview - MSN
Evercore ISI raises Illumina stock price target on strong results By Investing.com - Investing.com Canada
Evercore ISI raises Illumina stock price target on strong results - Investing.com
Florida Hospital Association adds Gaye Walker as communications VP - Florida Politics
ILMN SEC FilingsIllumina Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
MSN Money - MSN
Earnings Call Summary | Illumina(ILMN.US) Q1 2026 Earnings Conference - Moomoo
Illumina Q1 2026 slides: earnings beat on clinical strength, margins expand - Investing.com Canada
Illumina (NASDAQ:ILMN) Releases Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo News Malaysia
Illumina set to report earnings amid rising Roche competition - Investing.com
Illumina Q1 Earnings Call Highlights - Yahoo Finance
Illumina (ILMN) Q1 2026 Earnings Transcript - AOL.com
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance - MarketBeat
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises - Investing.com
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises By Investing.com - Investing.com South Africa
Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026 - Yahoo Finance
Illumina lifts 2026 outlook and expands share buybacks - TipRanks
Illumina Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Outlook - marketscreener.com
(ILMN) Illumina Expects Fiscal 2026 Adjusted EPS Range $5.15-$5.30, vs. FactSet Est of $5.12 - marketscreener.com
Illumina: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (ILMN) Illumina, Inc. Reports Q1 Revenue $1.09B, vs. FactSet Est of $1.07B - marketscreener.com
[8-K] ILLUMINA, INC. Reports Material Event - Stock Titan
Illumina, Inc. announces an Equity Buyback for $1,500 million worth of its shares. - marketscreener.com
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR Newswire
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):